This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Dermatology, Other  • Alert me on articles by topic

George J. Hruza, MD, Section Editor

Arch Dermatol. 2007;143(8):1062.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this issue of the Archives, Weinfeld¹ presents a novel use of botulinum toxin type A for a very difficult to treat condition, notalgia paresthetica. The 2 patients described in her article were resistant to all standard therapeutic modalities (none of which are usually effective), whereas 1 to 2 treatments with botulinum toxin type A eliminated or greatly reduced their symptoms for at least 1 year. This case report exemplifies the ideal Cutting Edge article. It presents the case of a patient with a condition that is either difficult to effectively treat with existing methods or a patient who is resistant to treatment and describes a novel treatment not previously reported. Ideally, it should be a treatment that is easily available to the physician, such as the botulinum toxin type A used in Weinfeld's report.¹

The Cutting Edge section of the Archives was . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Successful Treatment of Notalgia Paresthetica With Botulinum Toxin Type A
Pamela Kirschner Weinfeld
Arch Dermatol. 2007;143(8):980-982.
EXTRACT | FULL TEXT